Detalles de la búsqueda
1.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096872
2.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919527
3.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Lancet Oncol
; 14(10): 989-98, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23902874
4.
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Cancer Discov
; 14(2): 274-289, 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37982575
5.
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Clin Cancer Res
; 29(23): 4751-4759, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773077
6.
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
Lancet Oncol
; 12(8): 763-72, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21723781
7.
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer.
Trials
; 23(1): 372, 2022 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35526005
8.
Genomic profile of advanced breast cancer in circulating tumour DNA.
Nat Commun
; 12(1): 2423, 2021 04 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33893289
9.
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Breast Cancer Res Treat
; 124(1): 153-61, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20730486
10.
Time to TEAM: exemestane, or tamoxifen then exemestane?
Lancet
; 377(9762): 280-1, 2011 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21256370
11.
TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).
Eur Thyroid J
; 6(4): 197-207, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28868260
12.
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA.
Nat Commun
; 12(1): 4479, 2021 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272402
13.
The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective.
Trials
; 15: 379, 2014 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25262026
14.
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
J Clin Oncol
; 30(7): 709-17, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22042946
15.
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
J Clin Oncol
; 29(24): 3247-54, 2011 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21768453
16.
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Lancet Oncol
; 8(2): 119-27, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17267326
Resultados
1 -
16
de 16
1
Próxima >
>>